List of Excipients in Branded Drug EXTINA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mylan Pharmaceuticals Inc	EXTINA	ketoconazole	0378-8136	ALCOHOL
Mylan Pharmaceuticals Inc	EXTINA	ketoconazole	0378-8136	CETYL ALCOHOL
Mylan Pharmaceuticals Inc	EXTINA	ketoconazole	0378-8136	CITRIC ACID MONOHYDRATE
Mylan Pharmaceuticals Inc	EXTINA	ketoconazole	0378-8136	POLYSORBATE 60
Mylan Pharmaceuticals Inc	EXTINA	ketoconazole	0378-8136	POTASSIUM CITRATE

Extina Excipient Strategy and Commercial Opportunities

Last updated: October 26, 2026

Extina is a prescription ketoconazole 2% topical aerosol foam for seborrheic dermatitis. Its commercial value is tied less to ketoconazole itself than to the foam vehicle, propellant system, skin feel, dosing convenience, and manufacturing know-how. The principal opportunity is to develop an equivalent or differentiated foam that matches Extina's performance while reducing formulation, packaging, or supply-chain costs.

What is Extina and how does its formulation work?

Extina contains ketoconazole at a concentration of 2% in a pressurized topical foam. The FDA-approved indication is topical treatment of seborrheic dermatitis in immunocompetent patients 12 years of age and older.[1]

The formulation combines:

• Ketoconazole, the antifungal active ingredient
• Fatty alcohols, principally cetyl alcohol and stearyl alcohol
• Propylene glycol
• Mineral oil
• Polysorbate 60
• Acidifying and preservative agents
• Purified water
• A hydrocarbon propellant system

The product is dispensed as a foam from an aerosol container. The foam melts rapidly on contact with skin and hair, which supports application to the scalp and other hair-bearing areas.

What are the listed Extina excipients?

Public FDA labeling identifies the following inactive ingredients for Extina or ketoconazole foam products with the same or substantially similar formulation architecture:

Excipient or component	Functional role
Cetyl alcohol	Emollient, consistency agent, foam-structure modifier
Stearyl alcohol	Emollient, thickener, stabilizer
Polysorbate 60	Nonionic surfactant and emulsifier
Propylene glycol	Solvent, humectant, penetration-supporting vehicle
Mineral oil	Emollient and oil-phase component
Citric acid	pH adjustment
Benzoic acid or potassium sorbate	Preservative system, depending on product version
Purified water	Aqueous phase
Hydrocarbon propellants	Aerosolization and foam generation

The exact excipient declaration should be taken from the applicable FDA package insert and current product labeling because formulation and manufacturing ownership have changed across product versions.[1,2]

What is the excipient strategy behind Extina?

Extina's excipient strategy is based on a two-phase emulsion and hydrocarbon foam system. The formulation must keep ketoconazole uniformly distributed, generate a stable foam during dispensing, spread across scalp and facial skin, and collapse quickly enough to avoid leaving a heavy residue.

How do the fatty alcohols support commercial performance?

Cetyl alcohol and stearyl alcohol are central to the vehicle. They provide:

• Emollience and reduced skin roughness
• Viscosity control
• Oil-phase structure
• Foam texture and collapse behavior
• Improved product spreadability

The ratio between cetyl alcohol and stearyl alcohol can materially affect product performance. Higher long-chain alcohol content generally produces a denser and more persistent structure, while lower levels can improve melt-away behavior but may weaken foam stability.

For a generic or follow-on product, these excipients are not interchangeable on a simple weight-for-weight basis. Changes can affect:

• Foam density
• Dispensed mass
• Droplet size
• Residual greasiness
• Drug release
• Scalp deposition
• Container performance
• Patient handling

What is the role of propylene glycol?

Propylene glycol functions as a solvent and humectant. It can improve wetting and help maintain the drug in the formulation, but it can also contribute to stinging or irritation in susceptible users. A commercial reformulation that reduces propylene glycol could target improved tolerability, although the change would require comparative performance testing and regulatory support.

Why is the propellant system important?

The propellant affects the product's pressure, foam expansion, particle or droplet distribution, discharge rate, and residual product in the canister. Hydrocarbon propellants such as butane and isobutane are common in topical aerosol foams.

A propellant change can create regulatory and technical risk even if the active ingredient and nonvolatile excipients remain unchanged. The sponsor may need to demonstrate that the revised system maintains:

• Delivered dose uniformity
• Foam quality
• Drug distribution
• Stability
• Microbiological quality
• Container compatibility
• Flammability controls

What formulation patents protect Extina?

Publicly available patent and FDA records do not establish a broad, currently enforceable composition patent position that would independently prevent all ketoconazole foam competition. The commercial barrier is more likely to arise from the combined formulation, aerosol package, manufacturing process, trade secrets, and regulatory requirement to demonstrate pharmaceutical equivalence.

Extina's value is therefore better analyzed through a layered IP model:

IP or regulatory layer	Commercial relevance
Ketoconazole molecule	Old, off-patent active ingredient
Foam composition	May support formulation claims if patent claims remain enforceable
Aerosol container and valve	Can create engineering and supplier barriers
Manufacturing process	Often protected through know-how rather than public patents
Method of treatment	May cover seborrheic dermatitis use, subject to claim scope and expiration
Trademark	Protects the Extina brand, not the underlying formulation
FDA labeling	Defines the approved indication and product specifications
Trade secrets	May cover phase preparation, filling, temperature control, and batch release

A competitor must conduct a current United States Patent and Trademark Office and Orange Book review before relying on an assumed freedom to operate. Patent status can differ by jurisdiction and by claim type.

When does Extina lose exclusivity?

Extina's active ingredient, ketoconazole, has long been off patent. The relevant competitive question is not molecule exclusivity but whether any remaining formulation, method-of-use, regulatory, or commercial barriers delay an equivalent foam.

The key exclusivity categories are:

Exclusivity category	Extina position
New chemical entity exclusivity	Not applicable to ketoconazole
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	Any historical period would have expired
Formulation patent exclusivity	Requires current claim-by-claim verification
Method-of-use protection	Potentially relevant only if an unexpired, enforceable claim remains
Brand exclusivity	Trademark and market recognition continue after patent expiry
ANDA exclusivity	Relevant to the first qualifying generic applicant, not the brand

The practical market-opening event is FDA approval of a therapeutically equivalent generic or a competing 505(b)(2) product. For topical semisolid and aerosol products, approval may depend on comparative product quality and performance rather than conventional systemic bioequivalence alone.[3]

What is the Orange Book status of Extina?

Extina is an FDA-listed prescription topical product, but the commercial significance of its Orange Book record depends on the current listing, active patent entries, and whether a specific product remains marketed. Orange Book listings can change as sponsors update marketing status, patent certifications, or product ownership.

For a competitor, the relevant review should include:

1. Extina's current marketing status.
2. Listed patents and their expiration dates.
3. Whether any listed patent is identified as a formulation, method-of-use, or packaging patent.
4. Whether an ANDA applicant would need Paragraph IV certification.
5. Whether the reference listed drug remains eligible for ANDA reliance.
6. Whether an alternative pathway, including a 505(b)(2) application, is commercially preferable.

The Orange Book does not capture every potentially relevant patent. It generally does not provide a complete record of manufacturing trade secrets, supplier agreements, foreign patents, or unlisted formulation claims.[4]

What generic entry risks exist for Extina?

Generic entry risk is moderate to high at the active-ingredient level but more complex at the dosage-form level.

ANDA pathway

A conventional generic sponsor would seek approval by referencing the Extina reference listed drug. The main technical challenges are:

• Matching the foam's physical characteristics
• Demonstrating equivalent active-ingredient content
• Establishing comparable drug release
• Controlling aerosol delivery
• Matching container-closure performance
• Demonstrating microbial quality and stability
• Addressing local tolerability

A Paragraph IV challenge could target any unexpired listed formulation or method-of-use patent. If no relevant listed patent remains, an ANDA applicant could use a Paragraph III certification or another applicable certification.

505(b)(2) pathway

A 505(b)(2) product could support a differentiated foam, pump foam, gel, cream, or alternative vehicle. This route may be appropriate where the applicant changes:

• Propellant
• Container system
• Preservative
• Drug concentration
• Application site
• Dosing instructions
• Foam-generating technology

The trade-off is greater development flexibility but potentially greater clinical and regulatory burden.

Which companies could challenge Extina?

Competition can come from three groups:

Competitor type	Likely product
ANDA sponsors	Ketoconazole 2% aerosol foam
505(b)(2) developers	Reformulated ketoconazole foam or alternative delivery system
OTC and prescription competitors	Ketoconazole shampoo, creams, corticosteroid-antifungal combinations, and nonprescription dandruff treatments

Potential commercial competitors include manufacturers with capabilities in topical generics, aerosol filling, dermatology products, and contract manufacturing. The most credible entrants are companies that already operate hydrocarbon aerosol lines or have access to specialized topical foam manufacturing.

No biosimilar pathway applies. Extina is a small-molecule topical drug, not a biologic. Biosimilar risk is therefore irrelevant to the product's competitive assessment.

What commercial opportunities exist in Extina excipients?

Lower-cost equivalent foam

The most direct opportunity is a generic foam that retains Extina's functional excipient architecture while lowering:

• Raw-material costs
• Aerosol component costs
• Filling costs
• Packaging costs
• Distribution expense

Savings may come from alternate suppliers of fatty alcohols, surfactants, propellant, or canisters. Any substitution must preserve critical quality attributes.

Propellant reformulation

A lower-global-warming-potential propellant could offer regulatory and environmental positioning. The developer would need to manage changes in vapor pressure, flammability, foam texture, and dose delivery. Propellant reformulation is technically attractive but carries higher development risk than changing a nonvolatile excipient.

Preservative-reduced or preservative-free products

A preservative-reduced formulation could address irritation concerns and appeal to dermatology patients with sensitive skin. The primary barriers are microbial control, in-use stability, and package integrity.

Non-aerosol foam systems

A pump-dispensed foam could reduce shipping constraints related to pressurized and flammable containers. It could also simplify filling and improve pharmacy handling. The product would need to reproduce the application and deposition profile expected from Extina.

Combination therapy

Ketoconazole foam could be combined with an anti-inflammatory active ingredient for short-term management of inflammatory seborrheic dermatitis. This strategy would create a new regulatory and IP profile, but it would also introduce safety, labeling, and clinical-development requirements.

Regional licensing and contract manufacturing

A company with a validated aerosol process could license its platform to dermatology companies or regional generic manufacturers. The most valuable assets would include:

• Validated foam manufacturing
• Qualified canister and valve suppliers
• Propellant-handling capability
• Scale-up data
• Stability data
• Regulatory dossiers
• Freedom-to-operate analysis

How strong is the Extina patent estate?

The patent estate appears weaker at the active-ingredient level and potentially stronger at the formulation and manufacturing levels. Its practical strength depends on whether unexpired claims cover the specific foam composition, aerosol system, or method of treatment that a competitor intends to commercialize.

Factor	Assessment
Ketoconazole molecule	Weak barrier because of age and broad generic availability
Foam dosage form	Moderate technical barrier
Excipient combination	Potentially meaningful if claims are narrow and enforceable
Aerosol package	Moderate engineering barrier
Manufacturing process	Potentially strong as confidential know-how
Clinical differentiation	Limited unless the product changes treatment performance
Generic substitution	Main source of erosion risk

A competitor should not assume that an alternative excipient automatically avoids infringement. Patent claims can cover ranges, functional relationships, or product-by-process limitations.

What patent litigation and settlement issues affect Extina?

No litigation conclusion should be drawn from the existence of an ANDA or a generic listing alone. If a Paragraph IV certification is filed, the brand owner may sue within the statutory period, potentially triggering a 30-month stay under the Hatch-Waxman framework.[5]

Key diligence points include:

• Whether a listed patent was asserted
• Whether the case involved formulation or method-of-use claims
• Whether the parties entered a launch-date settlement
• Whether the settlement was submitted to the Federal Trade Commission
• Whether authorized-generic rights were included
• Whether the agreement restricted supply, licensing, or manufacturing

Settlement agreements can materially change the effective generic entry date even where the listed patent expires earlier.

How does Extina compare with ketoconazole shampoo and cream?

Attribute	Extina foam	Ketoconazole shampoo	Ketoconazole cream
Primary use	Seborrheic dermatitis	Seborrheic dermatitis and dandruff	Cutaneous fungal infections
Application	Leave-on foam	Rinse-off product	Leave-on cream
Hair-bearing scalp use	Strong convenience profile	Strong cleansing profile	Less convenient
Vehicle differentiation	High	Moderate	Lower
Aerosol complexity	High	Low to moderate	Low
Manufacturing barrier	Higher	Lower	Lower
Generic substitution risk	Moderate to high	High	High
Excipient differentiation	Material	Moderate	Moderate

The foam's commercial advantage is convenience and scalp application. Its disadvantage is higher packaging, filling, flammability, and manufacturing complexity.

What is the revenue exposure from generic entry?

Revenue exposure depends on the brand's remaining market share, reimbursement, price premium, and the number of generic entrants. Topical generic markets commonly experience rapid price erosion after multiple entrants, but aerosol foams can erode more slowly because fewer manufacturers have appropriate filling and packaging capabilities.

A scenario framework is:

Scenario	Likely commercial effect
No approved equivalent	Brand retains pricing and distribution advantage
One approved generic	Moderate price pressure, limited immediate substitution
Two to three generics	Substantial reimbursement and pharmacy pressure
Multiple aerosol suppliers	Rapid price erosion
Differentiated pump or low-irritation product	Brand or follow-on premium may persist

Key Takeaways

• Extina is a ketoconazole 2% topical aerosol foam for seborrheic dermatitis.
• Its principal commercial differentiation comes from the foam vehicle and delivery system, not the ketoconazole molecule.
• Cetyl alcohol, stearyl alcohol, polysorbate 60, propylene glycol, mineral oil, water, acidifiers, preservatives, and hydrocarbon propellants define the formulation architecture.
• Generic entry is technically feasible but requires control of foam quality, aerosol delivery, stability, and container compatibility.
• The strongest commercial opportunities are lower-cost equivalents, alternative propellant systems, pump foams, preservative-reduced products, and regional licensing.
• Biosimilar risk does not apply.
• Current Orange Book listings, patent status, and litigation records must be reviewed before a launch or Paragraph IV strategy is adopted.

FAQs

Can Extina be reformulated without ketoconazole?

No. A product without ketoconazole would no longer be an Extina equivalent. It would require a different regulatory strategy and would compete as a new active-ingredient product.

Are cetyl alcohol and stearyl alcohol interchangeable in ketoconazole foam?

No. They may be substituted or adjusted only after demonstrating comparable foam structure, drug distribution, release, stability, and tolerability.

Can a company avoid Extina patents by using a pump dispenser?

Not automatically. A pump product may avoid claims limited to pressurized aerosol systems, but broader composition or method claims could still apply.

Is a ketoconazole foam eligible for automatic pharmacy substitution?

Only if FDA approval establishes the applicable therapeutic-equivalence designation and state substitution rules permit substitution. Dosage-form and product-specific requirements matter.

What is the most defensible commercial differentiation for an Extina follow-on?

A product with comparable antifungal performance and improved handling, reduced irritation, lower environmental impact, lower packaging cost, or a nonflammable pump-delivery system offers the clearest differentiation.

References

1. U.S. Food and Drug Administration. (n.d.). Extina (ketoconazole) foam, 2% prescribing information.
2. National Library of Medicine. (n.d.). DailyMed: Ketoconazole foam, 2%.
3. U.S. Food and Drug Administration. (2022). Draft guidance on topical dermatologic corticosteroids and topical products: Product quality and bioequivalence considerations.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).